Blister pack
Latest AstraZeneca AB Patents:
- Method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
- Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
- Dendrimer formulations
- GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
- PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS
Description
FIG. 1 is a top plan view of a blister back in folded condition showing our new design;
FIG. 2 is a right side elevational view thereof;
FIG. 3 is a left side elevational view thereof;
FIG. 4 is a front elevational view thereof;
FIG. 5 is a rear elevational view thereof;
FIG. 6 is a bottom plan view thereof;
FIG. 7 is a top perspective view thereof;
FIG. 8 is a bottom perspective view thereof;
FIG. 9 is a top perspective view thereof, with the blister pack in unfolded condition; and,
FIG. 10 is a bottom perspective view thereof.
Claims
The ornamental design for a blister pack, as shown.
Referenced Cited
U.S. Patent Documents
Patent History
Patent number: D455344
Type: Grant
Filed: Apr 6, 2001
Date of Patent: Apr 9, 2002
Assignee: AstraZeneca AB (Sodertalje)
Inventors: Christian Assargren (Bromma), Claes Friberg (Haninge)
Primary Examiner: Nanda Bondade
Attorney, Agent or Law Firm: White & Case LLP
Application Number: 29/139,837
Type: Grant
Filed: Apr 6, 2001
Date of Patent: Apr 9, 2002
Assignee: AstraZeneca AB (Sodertalje)
Inventors: Christian Assargren (Bromma), Claes Friberg (Haninge)
Primary Examiner: Nanda Bondade
Attorney, Agent or Law Firm: White & Case LLP
Application Number: 29/139,837
Classifications
Current U.S. Class:
D9/345
International Classification: 0903;
International Classification: 0903;